BeiGene (FRA:49BA) EBIT per Share : €-10.70 (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is BeiGene EBIT per Share?

BeiGene's EBIT per Share for the three months ended in Dec. 2023 was €-3.38. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €-10.70.

During the past 3 years, the average EBIT per Share Growth Rate was 16.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was 1.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was -59.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for BeiGene's EBIT per Share or its related term are showing as below:

FRA:49BA' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -231 Med: -76.9 Max: 16.5
Current: 16.5

During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of BeiGene was 16.50% per year. The lowest was -231.00% per year. And the median was -76.90% per year.

FRA:49BA's 3-Year EBIT Growth Rate is ranked better than
67.69% of 1306 companies
in the Biotechnology industry
Industry Median: 3.5 vs FRA:49BA: 16.50

BeiGene's EBIT for the three months ended in Dec. 2023 was €-352 Mil.

BeiGene EBIT per Share Historical Data

The historical data trend for BeiGene's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene EBIT per Share Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-14.39

-16.32

-13.72

-16.38

-10.61

BeiGene Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-4.26	-3.33	-2.81	-1.17	-3.38

BeiGene EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

BeiGene's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1107.494	/	104.387
=	-10.61

BeiGene's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-351.94	/	104.074
=	-3.38

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.70

BeiGene (FRA:49BA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

BeiGene EBIT per Share Related Terms

Thank you for viewing the detailed overview of BeiGene's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (FRA:49BA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (FRA:49BA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (FRA:49BA) Headlines

No Headlines